Akeso’s Bispecific Antibody AK139 Approved for Seven Phase II Trials in China
Akeso Advances AK139 Bispecific Antibody into Phase II Trials Akeso, Inc. (9926.HK) has received approval from China’s National Medical Products Administration (NMPA) to begin Phase II clinical trials for...

